Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

oietin and thrombopoietin. Mutational activation of JAK2 is observed in the majority of patients with polycythemia vera, essential thrombocythemia and myelofibrosis, and is thought to drive the inappropriate expansion of blood cells observed in these conditions. Other members of the JAK family play critical roles in regulating immune responses, including the anti-viral and anti-parasitic responses.

XL019 is a potent JAK2 inhibitor (IC50 = 2 nM) with excellent selectivity versus the other members of the JAK kinase family (JAK1 IC50 = 130 nM, JAK3 IC50 = 250 nM, TYK2 IC50 = 340 nM). It is active against both wild type and mutationally activated forms of JAK2, and in preclinical studies showed good oral bioavailability and pharmacodynamic properties. Preclinical safety studies showed that XL019 was well tolerated.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL019 and the timing of the initiation of pivotal trials for XL019. Words such
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
(Date:8/31/2015)... , August 31, 2015 ... BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, today announced ... MCTC), has identified several new genetic markers with ... in patients treated with bisphosphonate drugs and was ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) filing for carfilzomib based ... Controls (CMC) review division of the U.S. Food and ... information related to commercial-scale manufacturing of carfilzomib.  Onyx had ...
... NEW YORK, Oct. 7 Reportlinker.com announces that a ... European RIS/PACS Market ... European RIS/PACS market in terms of the challenges faced ... The main chapters of the research service include an ...
Cached Medicine Technology:Onyx Pharmaceuticals Provides Status Update on Carfilzomib 2Onyx Pharmaceuticals Provides Status Update on Carfilzomib 3Reportlinker Adds European RIS/PACS Market 2Reportlinker Adds European RIS/PACS Market 3
(Date:8/31/2015)... Santa Rosa Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Southern family of companies – has teamed up with fellow South Walton property ... organization focused on eliminating extreme poverty in remote parts of the world. The two ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, ... company’s second Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction ... Mary Hotel in Long Beach, CA. The meeting is open for registration from ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in ... , Starting September 1st they are offering pre and postnatal fitness classes on ... Healthy Baby." , More information can be found at 248-601-6683. , Women’s Excellence ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... The ... healthcare to Veterans residing across southwest Florida by hiring more doctors and nurses and ... list of expanded services. , In early July, Dr. Anthony Jabre was selected to ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... formed in 2008, the result of a merger of five of the busiest ... cooperatively, they could provide more cost-effective and higher quality care than they did ...
Breaking Medicine News(10 mins):Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Garden State Urology! 2
... a platinum-based anticancer drug that,s made enormous headway in ... damage that may be permanent and worsens even months ... Johns Hopkins researchers in the September issue of ... be the first effort to track oxaliplatin-based nerve damage ...
... Serena Gordon HealthDay Reporter , TUESDAY, Sept. 27 ... screening earlier than women, new research suggests. The study ... precancerous lesions (also called polyps or adenomas) in their colon ... women -- and to have them at an earlier age. ...
... habits of a romantic partner,s friends are more likely to ... an adolescent,s own friends or significant other, according to a ... Review. "Dating someone whose friends are big drinkers is ... drinking behaviors than are the drinking habits of the adolescent,s ...
... on aging are headed for meetings with their senators ... senior population, spurred by the first-ever Take Action Week ... nation,s largest interdisciplinary organization devoted to the field of ... period, these advocates will urge their elected leaders to ...
... JOLLA, CA -- September 27, 2011 -- Scripps Research ... $3.6 million MERIT (Method to Extend Research in Time) ... to study the risk factors for alcoholism in Native ... to better understand alcohol dependence and alcohol-related problems in ...
... Reporter , TUESDAY, Sept. 27 (HealthDay News) -- Many ... when the going gets slow, fiber seems to beat ... suggests. A review of nine studies with 640 ... has no known physical cause, found that fiber supplements ...
Cached Medicine News:Health News:Popular colorectal cancer drug may cause permanent nerve damage 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3Health News:Adolescents particularly susceptible to drinking habits of romantic partner's friends 2Health News:Congress must protect funds for aging America, advocates say 2Health News:Scripps research scientist wins $3.6 million NIH Method to Extend Research in Time award to study alcoholism in Native Americans 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 3
... is an Anterior Cervical Plating System ... flexibility and simplicity for the spinal ... function and safe fixation of the ... meet the needs of the spinal ...
... cervical spinal compression plate acc. to Matzen ... the cervical spine (HWS) with the exception ... immobilization of the fusion length until the ... fixed anteriorly on the vertebral bodies, if ...
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures....
... small things. The extremely small,HiLAN XS ... trailblazers of the new,generation of miniaturized ... smaller access and the demand for ... HiLAN XS motor concept is the ...
Medicine Products: